Quick Answer
Estrella Immunopharma, Inc. reported Research And Development Expense of $10.25 million for the year ending 2025.
- Estrella Immunopharma, Inc. showed an increase of +149.4% in Research And Development Expense from 2024 to 2025.
- This data is from Estrella Immunopharma, Inc.'s annual report (Form 10-K), filed with the SEC on March 18, 2026.
- XBRL data for this metric is available from 2023 to 2025 (3 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q3 2022: $2.61 million | Q4 2022: $2.61 million | Q1 2023: $2.62 million | Q3 2023: $483.5 thousand | Q4 2023: $75.5 thousand | Q1 2024: $25.0 thousand | Q2 2024: $3.53 million | Q3 2024: $2.83 million | Q1 2025: $1.41 million | Q2 2025: $4.66 million | Q3 2025: $4.15 million.
- Over the full 3 years of available data (2023 to 2025), Estrella Immunopharma, Inc.'s Research And Development Expense has declined by 1.9%.
- Historical annual values: Fiscal year 2025: $10.25 million | Fiscal year 2024: $4.11 million | Fiscal year 2023: $10.45 million.
- Data sourced from SEC EDGAR public filings as of August 8, 2026.
Last verified: